vs
安进（AMGN）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是HALOZYME THERAPEUTICS, INC.的21.8倍（$9.9B vs $451.8M）。安进净利率更高（13.5% vs -31.3%，领先44.9%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs 8.6%）。安进自由现金流更多（$961.0M vs $217.6M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs 15.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
AMGN vs HALO — 直观对比
营收规模更大
AMGN
是对方的21.8倍
$451.8M
营收增速更快
HALO
高出43.0%
8.6%
净利率更高
AMGN
高出44.9%
-31.3%
自由现金流更多
AMGN
多$743.4M
$217.6M
两年增速更快
HALO
近两年复合增速
15.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $451.8M |
| 净利润 | $1.3B | $-141.6M |
| 毛利率 | 69.8% | 82.6% |
| 营业利润率 | 27.6% | -20.6% |
| 净利率 | 13.5% | -31.3% |
| 营收同比 | 8.6% | 51.6% |
| 净利润同比 | 112.6% | -203.3% |
| 每股收益（稀释后） | $2.45 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNHALO
| Q4 25 | $9.9B | $451.8M | ||
| Q3 25 | $9.6B | $354.3M | ||
| Q2 25 | $9.2B | $325.7M | ||
| Q1 25 | $8.1B | $264.9M | ||
| Q4 24 | $9.1B | $298.0M | ||
| Q3 24 | $8.5B | $290.1M | ||
| Q2 24 | $8.4B | $231.4M | ||
| Q1 24 | $7.4B | $195.9M |
净利润AMGNHALO
| Q4 25 | $1.3B | $-141.6M | ||
| Q3 25 | $3.2B | $175.2M | ||
| Q2 25 | $1.4B | $165.2M | ||
| Q1 25 | $1.7B | $118.1M | ||
| Q4 24 | $627.0M | $137.0M | ||
| Q3 24 | $2.8B | $137.0M | ||
| Q2 24 | $746.0M | $93.2M | ||
| Q1 24 | $-113.0M | $76.8M |
毛利率AMGNHALO
| Q4 25 | 69.8% | 82.6% | ||
| Q3 25 | 67.8% | 84.4% | ||
| Q2 25 | 67.2% | 85.8% | ||
| Q1 25 | 63.6% | 81.7% | ||
| Q4 24 | 65.7% | 85.9% | ||
| Q3 24 | 61.1% | 83.0% | ||
| Q2 24 | 61.4% | 82.9% | ||
| Q1 24 | 57.0% | 85.5% |
营业利润率AMGNHALO
| Q4 25 | 27.6% | -20.6% | ||
| Q3 25 | 26.4% | 61.5% | ||
| Q2 25 | 28.9% | 62.2% | ||
| Q1 25 | 14.5% | 53.4% | ||
| Q4 24 | 25.4% | 58.9% | ||
| Q3 24 | 24.1% | 56.3% | ||
| Q2 24 | 22.8% | 50.7% | ||
| Q1 24 | 13.3% | 48.8% |
净利率AMGNHALO
| Q4 25 | 13.5% | -31.3% | ||
| Q3 25 | 33.7% | 49.5% | ||
| Q2 25 | 15.6% | 50.7% | ||
| Q1 25 | 21.2% | 44.6% | ||
| Q4 24 | 6.9% | 46.0% | ||
| Q3 24 | 33.3% | 47.2% | ||
| Q2 24 | 8.9% | 40.3% | ||
| Q1 24 | -1.5% | 39.2% |
每股收益（稀释后）AMGNHALO
| Q4 25 | $2.45 | $-1.13 | ||
| Q3 25 | $5.93 | $1.43 | ||
| Q2 25 | $2.65 | $1.33 | ||
| Q1 25 | $3.20 | $0.93 | ||
| Q4 24 | $1.17 | $1.06 | ||
| Q3 24 | $5.22 | $1.05 | ||
| Q2 24 | $1.38 | $0.72 | ||
| Q1 24 | $-0.21 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $133.8M |
| 总债务越低越好 | $54.6B | $2.1B |
| 股东权益账面价值 | $8.7B | $48.8M |
| 总资产 | $90.6B | $2.5B |
| 负债/权益比越低杠杆越低 | 6.31× | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资AMGNHALO
| Q4 25 | $9.1B | $133.8M | ||
| Q3 25 | $9.4B | $419.7M | ||
| Q2 25 | $8.0B | $61.9M | ||
| Q1 25 | $8.8B | $176.3M | ||
| Q4 24 | $12.0B | $115.8M | ||
| Q3 24 | $9.0B | $154.3M | ||
| Q2 24 | $9.3B | $187.9M | ||
| Q1 24 | $9.7B | $164.6M |
总债务AMGNHALO
| Q4 25 | $54.6B | $2.1B | ||
| Q3 25 | $54.6B | $1.5B | ||
| Q2 25 | $56.2B | $1.5B | ||
| Q1 25 | $57.4B | $1.5B | ||
| Q4 24 | $60.1B | $1.5B | ||
| Q3 24 | $60.4B | $1.5B | ||
| Q2 24 | $62.6B | $1.5B | ||
| Q1 24 | $64.0B | $1.5B |
股东权益AMGNHALO
| Q4 25 | $8.7B | $48.8M | ||
| Q3 25 | $9.6B | $503.9M | ||
| Q2 25 | $7.4B | $332.7M | ||
| Q1 25 | $6.2B | $482.3M | ||
| Q4 24 | $5.9B | $363.8M | ||
| Q3 24 | $7.5B | $452.7M | ||
| Q2 24 | $5.9B | $289.4M | ||
| Q1 24 | $5.0B | $177.8M |
总资产AMGNHALO
| Q4 25 | $90.6B | $2.5B | ||
| Q3 25 | $90.1B | $2.2B | ||
| Q2 25 | $87.9B | $2.1B | ||
| Q1 25 | $89.4B | $2.2B | ||
| Q4 24 | $91.8B | $2.1B | ||
| Q3 24 | $90.9B | $2.1B | ||
| Q2 24 | $90.9B | $2.0B | ||
| Q1 24 | $93.0B | $1.8B |
负债/权益比AMGNHALO
| Q4 25 | 6.31× | 43.89× | ||
| Q3 25 | 5.67× | 3.00× | ||
| Q2 25 | 7.57× | 4.54× | ||
| Q1 25 | 9.24× | 3.13× | ||
| Q4 24 | 10.23× | 4.14× | ||
| Q3 24 | 8.02× | 3.32× | ||
| Q2 24 | 10.57× | 5.19× | ||
| Q1 24 | 12.75× | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $217.6M |
| 自由现金流率自由现金流/营收 | 9.7% | 48.2% |
| 资本支出强度资本支出/营收 | 6.5% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | $644.6M |
8季度趋势，按日历期对齐
经营现金流AMGNHALO
| Q4 25 | $1.6B | $219.0M | ||
| Q3 25 | $4.7B | $178.6M | ||
| Q2 25 | $2.3B | $99.7M | ||
| Q1 25 | $1.4B | $154.2M | ||
| Q4 24 | $4.8B | $178.5M | ||
| Q3 24 | $3.6B | $115.4M | ||
| Q2 24 | $2.5B | $55.8M | ||
| Q1 24 | $689.0M | $129.4M |
自由现金流AMGNHALO
| Q4 25 | $961.0M | $217.6M | ||
| Q3 25 | $4.2B | $175.6M | ||
| Q2 25 | $1.9B | $98.1M | ||
| Q1 25 | $980.0M | $153.3M | ||
| Q4 24 | $4.4B | $175.4M | ||
| Q3 24 | $3.3B | $113.9M | ||
| Q2 24 | $2.2B | $53.2M | ||
| Q1 24 | $459.0M | $125.9M |
自由现金流率AMGNHALO
| Q4 25 | 9.7% | 48.2% | ||
| Q3 25 | 44.4% | 49.6% | ||
| Q2 25 | 20.8% | 30.1% | ||
| Q1 25 | 12.0% | 57.9% | ||
| Q4 24 | 48.4% | 58.9% | ||
| Q3 24 | 39.0% | 39.3% | ||
| Q2 24 | 26.5% | 23.0% | ||
| Q1 24 | 6.2% | 64.3% |
资本支出强度AMGNHALO
| Q4 25 | 6.5% | 0.3% | ||
| Q3 25 | 4.6% | 0.9% | ||
| Q2 25 | 4.0% | 0.5% | ||
| Q1 25 | 5.0% | 0.4% | ||
| Q4 24 | 4.1% | 1.0% | ||
| Q3 24 | 3.0% | 0.5% | ||
| Q2 24 | 2.8% | 1.1% | ||
| Q1 24 | 3.1% | 1.8% |
现金转化率AMGNHALO
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | 1.02× | ||
| Q2 25 | 1.59× | 0.60× | ||
| Q1 25 | 0.80× | 1.31× | ||
| Q4 24 | 7.61× | 1.30× | ||
| Q3 24 | 1.26× | 0.84× | ||
| Q2 24 | 3.30× | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
